January 2020 FDA Recall Drug by Lupin Pharmaceuticals Inc.
D-0790-2020 - CGMP Deviations

This Class III drug recall was voluntarily initiated by Lupin Pharmaceuticals Inc. on January 10, 2020 for the product Drug. The FDA reported the reason for recall as cgmp deviations. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0790-2020

Reason for Recall
CGMP Deviations: Out of specification test result observed during retrospective review of blend uniformity test data.
Initiated
01-10-2020
Reported
01-22-2020
Quantity
34,080 boxes (3 wallets per carton, 80 cartons per box)

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Lupin Pharmaceuticals Inc.
Distributed nationwide in the US
Tri-Lo-Marzia (Norgestimate and Ethinyl Estradiol Tablets, USP), 0.180 mg/0.025 mg; 0.215mg/0.025 mg and 0.250 mg/0.025 mg, Pack size - 3 x 28's wallets/carton, Rx Only, Distributed by Lupin Pharmaceuticals, Inc, Baltimore MD 21202, Manufactured by: Lupin Limited, Pithampur, (M.P.)- 454775, India. NDC 68180-837-13 (3x28 carton ) NDC 68180-837-11 (28 tablet wallet)

Batch or Lot Expiration Information

Lot# L800498, exp. date February 2020